Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 566, Issue 1-3, Pages 132-136Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejphar.2007.03.031
Keywords
delta-opioid; anti-depressant; naltrindole; tail-suspension test; naltrexone; nor-binaltorphimine hydrochloride (nor-BNI)
Categories
Funding
- NIDA NIH HHS [R01 DA015683-03, P01 DA017259, DA3-8823, DA017259, R01 DA015683, DA015683, DA1-7725, P01 DA017259-010003] Funding Source: Medline
Ask authors/readers for more resources
The present study examined the effects of NIH 11082 ((-)-(1R,5R,9R)-5,9-dimethyl-2'-hydroxy-2-(6-hydroxyhexyl)-6,7-benzomorphan hydrochloride), a benzomorphan analogue, in the mouse tail-suspension, an assay used to detect anti-depressant agents. NIH 11082 significantly decreased immobility time during tail-suspension, with a comparable magnitude as the tricyclic anti-depressant desipramine. Importantly, NIH 11082 failed to elicit convulsions or other overt behavioral signs of toxicity. The delta-opioid receptor antagonist naltrindole (AD(50) = 2.0 mg/kg), but not the non-selective mu-opioid receptor antagonist naltrexone or the kappa-opioid receptor antagonist nor-BNI, blocked the effects of NIH 11082 in the tail-suspension test. These results reinforce the notion that delta-opioid receptor agonists can produce significant effects in a behavioral model used to screen anti-depressant drugs. (c) 2007 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available